CL2016002020A1 - Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor - Google Patents

Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Info

Publication number
CL2016002020A1
CL2016002020A1 CL2016002020A CL2016002020A CL2016002020A1 CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1 CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1
Authority
CL
Chile
Prior art keywords
plp
cofactor
erythrocytes
encapsulate
envelope
Prior art date
Application number
CL2016002020A
Other languages
English (en)
Spanish (es)
Inventor
Yann Godfrin
Vanessa Bourgeaux
Fabien Gay
Thomas Cortese
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of CL2016002020A1 publication Critical patent/CL2016002020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
CL2016002020A 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor CL2016002020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451100A FR3017299B1 (fr) 2014-02-12 2014-02-12 Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur

Publications (1)

Publication Number Publication Date
CL2016002020A1 true CL2016002020A1 (es) 2017-06-23

Family

ID=50729647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002020A CL2016002020A1 (es) 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Country Status (17)

Country Link
US (3) US10046009B2 (OSRAM)
EP (2) EP3718562A1 (OSRAM)
JP (1) JP6563958B2 (OSRAM)
KR (1) KR102354103B1 (OSRAM)
CN (2) CN111358941B (OSRAM)
AU (2) AU2015217045B2 (OSRAM)
BR (1) BR112016017337B1 (OSRAM)
CA (1) CA2938469C (OSRAM)
CL (1) CL2016002020A1 (OSRAM)
ES (1) ES2808849T3 (OSRAM)
FR (1) FR3017299B1 (OSRAM)
IL (1) IL246941B (OSRAM)
JO (1) JO3522B1 (OSRAM)
MX (1) MX378781B (OSRAM)
RU (2) RU2744659C2 (OSRAM)
SG (2) SG10201907367QA (OSRAM)
WO (1) WO2015121348A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
AU2017207304B2 (en) 2016-01-11 2022-05-26 Epicentrx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CN115969987A (zh) 2016-01-11 2023-04-18 鲁比厄斯治疗法股份有限公司 与免疫适应症的多模式治疗性细胞体系有关的组合物和方法
BR112018074716A2 (pt) 2016-06-02 2019-03-12 Sanofi conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose
IL311727A (en) 2017-07-07 2024-05-01 Epicentrx Inc Preparations for intravenous administration of medical substances
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US11001826B2 (en) 2017-10-19 2021-05-11 Anticancer, Inc. Orally administered composition to lower serum methionine levels and method of use
US20210170033A1 (en) 2017-12-01 2021-06-10 Sanofi Novel conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20210403571A1 (en) 2018-11-15 2021-12-30 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
SG11202111842SA (en) 2019-04-26 2021-11-29 Rubius Therapeutics Inc Buffered compositions including enucleated erythroid cells
CN114127252A (zh) 2019-05-24 2022-03-01 鲁比厄斯治疗法股份有限公司 生成去核红系细胞的方法
JP2023500327A (ja) 2019-11-04 2023-01-05 ルビウス セラピューティクス， インコーポレイテッド ミオイノシトールを使用して除核赤芽球細胞を生成する方法
KR20220093196A (ko) 2019-11-04 2022-07-05 루비우스 테라퓨틱스, 아이엔씨. 타우린 또는 하이포타우린을 사용하여 제핵 적혈구 세포를 생성하는 방법
CA3178252A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
EP4341395A4 (en) * 2021-05-21 2025-07-23 Syntis Bio Inc MODIFIED METHIONINE GAMMA LYASE VARIANTS
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
CN113481253B (zh) * 2021-06-09 2022-05-24 连云港杰瑞药业有限公司 生物催化制备磷酸吡哆醛的方法
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2025219395A1 (en) 2024-04-16 2025-10-23 Chu D'angers Treatment of cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1354204A (fr) 1963-01-22 1964-03-06 Auxiliaire De L Entpr Soc Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5631271A (en) * 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
KR100530976B1 (ko) 1997-03-13 2005-11-24 시오노기세이야쿠가부시키가이샤 엘-메티오닌 감마-리아제 결정의 제조방법
AU2002211512A1 (en) * 2000-10-06 2002-04-15 Millennium Pharmaceuticals, Inc. 25219, a novel human aminotransferase and uses therefor
CN1863551A (zh) * 2003-07-31 2006-11-15 抗癌公司 用于提高在体内的效力的PLP和PEG－rMETase的用途
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
RU2362572C2 (ru) * 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
EP2242507B1 (en) 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
CN101429506A (zh) * 2008-12-15 2009-05-13 吉林大学 基于红细胞载体的fish-in-net固定化酶
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
PT2493487T (pt) 2009-10-27 2016-11-08 Erytech Pharma Composição para induzir uma tolerância imunitária específica
EP2827878A1 (en) 2012-03-21 2015-01-28 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
US11458170B2 (en) 2022-10-04
WO2015121348A3 (en) 2015-10-08
EP3718562A1 (en) 2020-10-07
US20160361361A1 (en) 2016-12-15
ES2808849T3 (es) 2021-03-02
RU2744659C2 (ru) 2021-03-12
CN106255506A (zh) 2016-12-21
IL246941A0 (en) 2016-09-29
MX2016010235A (es) 2016-10-28
AU2015217045B2 (en) 2018-03-08
AU2015217045A1 (en) 2016-08-18
EP3104875B1 (en) 2020-05-06
FR3017299A1 (fr) 2015-08-14
JP2017506260A (ja) 2017-03-02
WO2015121348A2 (en) 2015-08-20
US20210008114A1 (en) 2021-01-14
CN111358941A (zh) 2020-07-03
RU2019123935A3 (OSRAM) 2020-03-26
US20180344771A1 (en) 2018-12-06
CN111358941B (zh) 2023-12-01
RU2016133315A (ru) 2018-02-16
MX378781B (es) 2025-03-11
CN106255506B (zh) 2020-04-14
CA2938469C (en) 2023-03-14
SG10201907367QA (en) 2019-09-27
KR102354103B1 (ko) 2022-01-24
US10046009B2 (en) 2018-08-14
RU2016133315A3 (OSRAM) 2018-09-26
RU2019123935A (ru) 2019-10-03
EP3104875A2 (en) 2016-12-21
KR20160121532A (ko) 2016-10-19
CA2938469A1 (en) 2015-08-20
FR3017299B1 (fr) 2018-05-18
JO3522B1 (ar) 2020-07-05
RU2697086C2 (ru) 2019-08-12
IL246941B (en) 2019-09-26
AU2018201237A1 (en) 2018-03-15
BR112016017337B1 (pt) 2022-08-09
AU2018201237B2 (en) 2019-09-26
BR112016017337A2 (OSRAM) 2017-08-08
SG11201606264SA (en) 2016-08-30
US10780126B2 (en) 2020-09-22
JP6563958B2 (ja) 2019-08-21

Similar Documents

Publication Publication Date Title
CL2016002020A1 (es) Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor
EP3447085A4 (en) CELLULOSIC RESIN COMPOSITION AND CELLULOSE COMPONENT
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
HUE053619T2 (hu) Anti-CD123 antitestek és konjugátumok és ezek származékai
ES2715251R1 (es) Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina
EP3500255A4 (en) PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE
EP3355847A4 (en) ASEPTIC COMPOSITION OF PHARMACEUTICAL CONTAINERS
PT2991511T (pt) Material vaporizável e cápsula
EP3341007A4 (en) MALT1 INHIBITORS AND USES THEREOF
EP3434285A4 (en) PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
EP3463345A4 (en) PHARMACEUTICAL COMBINATIONS
EP3405044A4 (en) BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF
BR112016028188A2 (pt) embalagens e método de fabricação da mesma
FI20155027A7 (fi) Polymyksiinijohdannainen ja sen käytöt
PT3320903T (pt) Composição farmacêutica contendo amlodipina, valsartan e rosuvastatina
MA49837A (fr) Compositions pharmaceutiques
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
EP2994197A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
LT3226905T (lt) Hialuronano konjugatai su farmaciniu požiūriu aktyviomis medžiagomis, būdai ir kompozicijos
FI20145984A7 (fi) Substituoitua bentsofurokinolitsiinia ja ɑ2-adrenergista agonistia käsittävät koostumukset
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
EP3302513A4 (en) COMPOSITION AND USES THEREOF
FI20155009A7 (fi) Pakkausaihio ja pakkaus
EP3302483A4 (en) PHARMACEUTICAL COMPOSITIONS AND USE THEREOF